Avalo Therapeutics to Participate in Multiple Investor Conferences in September

WAYNE, Pa., Sept. 03, 2026 /CourierPR/ -- Avalo Therapeutics, a clinical-stage biotechnology company focusing on developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, will participate in several upcoming investor conferences to showcase its progress and engage with investors.

On September 10, 2026, at 8:00 am Eastern Time, Avalo's management will participate in a fireside chat at the Cantor Global Healthcare Conference 2026. Later that week, from September 16 to 24, the company will present at three other major events: the Morgan Stanley 24th Annual Global Healthcare Conference, the H.C. Wainwright 28th Annual Global Investment Conference, and the Stifel 2026 Virtual Immunology and Inflammation Forum. These sessions will be held on September 16 and 24, 2026, at 8:30 am and 9:30 am Eastern Time, respectively.

Attendees and interested parties can access live webcasts and replays through Avalo's website at https://ir.avalotx.com under the "News / Events" section. The webcasts will remain available for at least 30 days after their initial airing.

Avalo Therapeutics, based on its dedication to addressing immune-mediated inflammatory diseases, is advancing its lead anti-IL-1β monoclonal antibody (mAb) drug candidate, abdakibart, into a phase 3 registrational program for the treatment of hidradenitis suppurativa (HS). HS is a chronic inflammatory skin condition that affects approximately 1 to 4 percent of the global population. The company is also exploring additional development opportunities in IL-1β-driven indications.